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ORIGINAL ARTICLE
Nationwide Outcome of Gastrectomy with En-Bloc Partial
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V. E. P. P. Lemmens7,8 & B. P. L. Wijnhoven1 & M. G. Besselink2 & M. I. van Berge Henegouwen2 & on behalf of the Dutch
Upper Gastrointestinal Cancer Audit (DUCA) group.
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Abstract
Background Radical gastrectomy is the cornerstone of the treatment of gastric cancer. For tumors invading the pancreas, en-bloc
partial pancreatectomy may be needed for a radical resection. The aim of this study was to evaluate the outcome of gastrectomies
with partial pancreatectomy for gastric cancer.
Methods Patients who underwent gastrectomy with or without partial pancreatectomy for gastric or gastro-oesophageal junction
cancer between 2011 and 2015 were selected from the Dutch Upper GI Cancer Audit (DUCA). Outcomes were resection margin
(pR0) and Clavien–Dindo grade ≥ III postoperative complications and survival. The association between partial pancreatectomy
and postoperative complications was analyzed with multivariable logistic regression. Overall survival of patients with partial
pancreatectomy was estimated using the Kaplan–Meier method.
Results Of 1966 patients that underwent gastrectomy, 55 patients (2.8%) underwent en-bloc partial pancreatectomy. A pR0
resection was achieved in 45 of 55 patients (82% versus 85% in the group without additional resection,P = 0.82). Clavien–Dindo
grade ≥ III complications occurred in 21 of 55 patients (38% versus 17%, P < 0.001). Median overall survival [95% confidence
interval] was 15 [6.8–23.2] months. For patients with and without perioperative systemic therapy, median survival was 20 [12.3–
27.7] and 10 [5.7–14.3] months, and for patients with pR0 and pR1 resection, it was 20 [11.8–28.3] and 5 [2.4–7.6] months,
respectively.
Conclusions Gastrectomy with partial pancreatectomy is not only associated with a pR0 resection rate of 82% but also with
increased postoperative morbidity. It should only be performed if a pR0 resection is feasible.
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Introduction
Themainstay of curative treatment in gastric cancer is surgery.
For patients with resectable gastric cancer of stage II or higher,
neoadjuvant or adjuvant chemotherapy is recommended.1 A
radical resection with tumor-negative resection margins (pR0
resection) is the most powerful predictor of survival.2,3
In patients with advanced gastric cancer, en-bloc partial pan-
createctomy may be needed to obtain a pR0 resection.
However, the benefits of en-bloc partial pancreatectomy should
be critically evaluated given the potential for increased morbid-
ity. Routine splenectomy in patients who underwent a D2 gas-
trectomy did not lead to increased survival.4–6 In the past, a
gastrectomy with pancreatosplenectomy was regarded as the
standard of care for gastric cancer because it was believed that
this would increase lymph node yield and thereby improve
oncological outcomes. Since two large trials demonstrated that
a D2 lymphadenectomy with pancreatosplenectomy increases
postoperative morbidity and mortality without any additional
beneficial effects on survival,7–9 current guidelines recommend
a D2 resection without pancreatosplenectomy.1 Nowadays, an
en-bloc partial pancreatectomy is only indicated for tumors that
invade the pancreas.1
The aim of this study was to evaluate patient characteristics
and outcomes of en-bloc partial pancreatectomies in patients
undergoing gastrectomy for gastric cancer in the Netherlands
between 2011 and 2015.
Methods
Study Population
For this study, the database of the Dutch Upper
Gastrointestinal Cancer Audit (DUCA) was used.
Participation in this national audit registry is mandatory for
all Dutch hospitals that perform oncological upper gastroin-
testinal surgery. All patients with gastric or oesophageal can-
cer who are scheduled to undergo resection are included.10 In
this audit, patient, disease, and treatment characteristics are
prospectively collected. Outcomes are registered until 30 days
postoperatively or during hospitalization. The completeness
of cases registered in the DUCA approached 100% of patients
registered in 2013.10
Patients who underwent gastrectomy between 2011 and
2015 were selected from the DUCA (Fig. 1). Patients with
missing 30-day mortality status (n = 27), date of birth (n =
3), or type of procedure (n = 4) were excluded. When a partial
pancreatectomy was registered as an additional surgical
procedure, details of patient, treatment, and (long-term) out-
come characteristics were provided by participating centers.
Patients in whom the partial pancreatectomy was erroneously
registered were excluded. For the comparison of patients with
and without partial pancreatectomy, patients with other addi-
tional resections than pancreatectomy (e.g., splenectomy)
were excluded. A separate analysis was executed to compare
the occurrence of complications, in patients with partial pan-
createctomy compared to patients with other additional (non-
pancreas) resections. Another subgroup analysis was executed
for patients with a pT4 tumor, the occurrence of complications
in patients with partial pancreatectomy was compared to the
occurrence of complications in patients without a partial
pancreatectomy.
Outcomes
The prevalence of partial pancreatectomy for gastric cancer
was analyzed for all individual hospitals. Characteristics and
short-term outcomes of patients with a partial pancreatectomy
were evaluated and compared with patients with no additional
resection. Also, short-term outcomes were described for both
groups: duration of hospital stay, intensive care unit (ICU)
stay, resection margins (tumor negative: pR0, microscopically
positive: pR1, macroscopically positive: pR2), postoperative
complications, postoperative Clavien–Dindo grade ≥ III com-
plications (defined as a complication in combination with a
reintervention, readmission to the intensive care unit/medium
care unit or death), and 30-day/in-hospital mortality.
Disease-free and overall survival for patients with partial
pancreatectomy were evaluated. The following subgroups
within the partial pancreatectomy group were compared:
pR0 versus pR1 resections and perioperative systemic therapy
versus no perioperative systemic therapy.
Statistical Analysis
Characteristics and short-term outcomes of patients who
underwent gastrectomy with and without partial pancreatecto-
my were compared using Mann–Whitney U test and chi-
square test, when appropriate. The association between partial
pancreatectomy and complications was tested with
univariable and multivariable logistic regression analysis. In
the multivariable analysis, clinically relevant variables were
added to the model, as well as the variables that were associ-
ated with complications (P value < 0.10 in univariable analy-
ses). The association was tested for sex, age, Charlson comor-
bidity score,11 American Society of Anaestesiologists (ASA)
score, tumor location, cT category, and cN category. Overall
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survival was estimated using the Kaplan–Meier method, and
subgroups were compared with log-rank analysis. All analy-




Between 2011 and 2015, 2192 patients who underwent a gas-
trectomy for gastric cancer were registered in the DUCA da-
tabase. Additional resections were performed in 177 of 2192
patients (8.1%). An additional partial pancreatectomy was
performed in 70 of 2192 patients (3.2%) (Fig. 1). The percent-
age gastrectomies with additional partial pancreatectomy var-
ied between 0 and 10% for the individual hospitals.
Some 55 of 70 patients who underwent additional partial
pancreatectomy were included in the analysis because all data
could be retrieved from the patient charts. After exclusion of
patients with incomplete data, 1911 patients without addition-
al resections served as the control group.
Patient demographics are shown in Table 1. In 12 of 55
patients who underwent a partial pancreatectomy, the tumor
was staged preoperatively as cT4. In all 55 patients a preop-
erative CT scan was performed. In 15/55 (27%) patients, pre-
operative EUS was performed.
In the additional pancreatectomy group, total gastrectomy
was performed in 31 patients (56%), and 34 patients received
perioperative systemic therapy (62%) (Table 2). Additional
resections of adjacent organs/structures were performed in
31 of 55 patients, including the spleen (n = 25), mesocolon
(n = 7), liver (n = 4), diaphragm (n = 1), and other (n = 10).
Five of 27 patients with a distal pancreatectomy did not un-
dergo a splenectomy. The remaining patients who underwent
a splenectomy, n = 3, underwent a wedge resection/pancreatic
head resection. Upon pathological examination, 34 (62%) tu-
mors were staged as pT4 (Table 2).
Operations
Nine of 55 patients (16%) underwent pancreatoduodenectomy,
27 (49%) distal pancreatectomy, and 19 (35%) a wedge resec-
tion (Table 3). In the vast majority (n = 52), the indication for
partial pancreatectomywas direct tumor ingrowth into the pan-
creas. Some 30 of 55 resections were performed by a surgeon
with experience in pancreatic surgery. In 6 (11%) procedures,
the surgical team was changed for the pancreatectomy.
A pR0 resection was achieved in 45 of 55 patients under-
going gastrectomy with partial pancreatectomy (82%)
(Table 4). This was not statistically significant different from
the patients who underwent a gastrectomy without additional
resection (1617 of 1911, 85%, P = 0.82).
Complications
In the partial pancreatectomy group, there were relatively more
patients with postoperative complications, n = 33 (60%) versus
Fig. 1 Patients who underwent gastrectomy between 2011 and 2015
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n = 703 (37%, P ≤ 0.001) (Table 4). Also, Clavien–Dindo grade
III and higher complications occurred more frequently in the
partial pancreatectomy group: in 21 (38%) patients versus 332
(17%) patients (< 0.001). An additional partial pancreatectomy
was independently associated with a complication with Clavien–
Dindo grade III or higher (OR [95% confidence interval (CI)]
3.28 [1.85–5.82] (Table 4). Postoperative pancreatic fistulas
grade B and C according to the International Study Group on
Pancreatic Surgery definition were observed in 9 (16%) and 2
(3.6%) patients, respectively (Table 5).12 Clavien–Dindo grade
III or higher occurred in 42/172 (24%) patients with other addi-
tional (non-pancreas) resections; this was not significantly differ-
ent from the partial pancreatectomy group (38%). For the sub-
group of patients with a pT4 tumor, 332/1911 (17%) patients in
the gastrectomy only group had a Clavien-Dindo grade III or
higher complication versus 4/24 (17%) of patients in the partial
Table 1 Patient and disease characteristics of patients undergoing gastrectomy with no additional resection and with additional partial pancreatectomy
Gastrectomy alone Gastrectomy plus partial pancreatectomy P value
n = 1911 (97%) n = 55 (2.8%)
n % n %
Gender 0.53
Male 1207 63% 37 67%
Female 704 37% 18 33%
Age (in years, median, IQR) 70 [62–77] 66 [57–73]
Age (in groups) 0.04
< 65 years 605 32% 22 40%
65–74 years 645 34% 23 42%
> 75 years 661 35% 10 18%
Charlson score < 0.001
0 835 44% 39 71%
1 458 24% 7 13%
2+ 618 32% 9 16%
ASA score 0.71
I-II 1293 68% 39 71%
III+ 600 31% 16 29%
Unknown 18 0.9% 0 0.0%
Location of tumor 0.05
Esophageal-gastric junction 69 3.6% 1 1.8%
Fundus 134 7.0% 8 15%
Corpus 556 29% 16 29%
Antrum 771 40% 13 24%
Pylorus 153 8.0% 9 16%
Entire stomach 95 5.0% 3 5.5%
Pouch 59 3.1% 3 5.5%
Unknown 74 3.9% 2 3.6%
cT category < 0.001
cT0–2 571 30% 2 3.6%
cT3 763 40% 27 49%
cT4 78 4.1% 12 22%
cTx 457 24% 14 26%
Missing 42 2.2% 0 0.0%
cN category 0.002
cN-0 976 51% 15 27%
cN+ 661 35% 28 51%
cNx 231 12% 12 22%
Missing 43 2.3% 0 0.0%
cM category 0.001
cM-0 1774 93% 49 89%
cM+ 24 1.3% 4 7.3%
cMx 113 5.9% 2 3.6%
TNM stage n.a.
Stage 0 33 1.8% 0 0.0%
Stage I 392 21% 1 1.8%
Stage II 637 35% 17 31%
Stage III 138 8% 8 15%
Stage IV 24 1.3% 3 5.5%
Stage unknown 687 36% 26 47%
IQR interquartile range, ASA American Society Anaesthesiologists, n.a. not available
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pancreatectomy group (P = 0.93). Combined in-hospital and 30-
day mortality was 7.3% (4 of 53) in patients with partial pancre-
atectomy versus 5.3% in patients without additional resections
(101 of 1911, P = 0.52) (Table 4).
Survival
Median follow-up of the patients with partial pancreatectomy
was 42 [95% CI 36.1–47.9] months. Median overall survival
was 15 [6.8–23.2] months (Fig. 2a), and median disease-free
Table 2 Treatment characteristics of patients undergoing gastrectomy with no additional resection and with additional partial pancreatectomy
Gastrectomy alone Gastrectomy plus partial pancreatectomy P value
Treatment n = 1911 (97%) n = 55 (2.8%)
n % n %
(Neo)adjuvant therapy 0.28
None 779 42% 21 38%
Neoadjuvant and adjuvant 688 37% 17 31%
Adjuvant 44 2% 3 6%
Neoadjuvant 358 19% 14 26%
Urgency of surgery 0.01
Elective 1833 96% 49 89%
Urgent/emergency 75 4% 6 11%
Unknown 3 0% 0 0%
Curative/palliative n.a.
Palliative 52 3% 3 6%
Curative 1835 96% 51 93%
Prophylactic resection 13 1% 0 0%
Unknown 11 1% 1 2%
Type of resection 0.03
Total gastrectomy 803 42% 31 56%
Partial gastrectomy 1108 58% 24 44%
Procedure n.a.
Open 1331 70% 44 80%
MI abdomen 489 26% 5 9%
MI abdomen converted 56 2.9% 6 11%
MI thorax 1 0.1% 0 0.0%
MI thorax and abdomen 14 0.7% 0 0.0%
MI thorax and abdomen converted 3 0.2% 0 0.0%
Unknown 17 1% 0 0%
Reconstruction n.a.
No reconstruction 36 2% 1 2%
Gastric tube 17 1% 1 2%
Coloninterponate 2 0% 0 0%
Jejunuminterponate 39 2.0% 0 0.0%
Esophagojejunostomy 776 41% 30 55%
Gastro-enterostomy 1007 53% 22 40%
Other 9 1% 1 2%
Unknown 25 1% 0 0%
Additional resections other than pancreatic 31 56%





Pathological T-stage < 0.001
pT0–2 728 38% 3 6%
pT3 753 39% 17 31%
pT4 371 19% 34 62%
pTx 29 2% 1 2%
Unknown 30 2% 0 0%
Annual volume in the hospital or resection 0.20
0–19 resections 1217 64% 37 67%
20–39 resections 481 25% 16 29%
40 or more resections 213 11% 2 4%
MI minimally invasive, n.a. not available
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survival was 13 [7.6–18] months (Fig. 2b). One-, 2-, and 3-
year survival rates were 56%, 38%, and 31%, respectively. In
patients in whom an pR0 resection was obtained, median
overall survival was 20 [11.8–28.3] months and for patients
with an pR1 resection, 5 [2.4–7.6] months (Fig. 2c). For pa-
tients treated with perioperative systemic therapy, median
overall survival was 20 [12.3–27.7] months versus 10 [5.7–
14.3] months for patients without perioperative systemic ther-
apy (Supplementary Fig. 1).
Discussion
A gastrectomy with en-bloc partial pancreatectomy was rarely
performed in the Netherlands between 2011 and 2015. The
intraoperative indication for partial pancreatectomy for gastric
cancer was usually direct tumor ingrowth in the pancreas. In
these patients, additional partial pancreatectomy was associat-
ed with an R0 resection rate of 82% but an increased risk for
complications.
This study gives a unique overview of the national outcome
of patients with gastric cancer for whom an additional partial
pancreatectomy was performed during gastrectomy. Most
studies on additional resections evaluated different
multivisceral resections as one group.4,13,14 The national audit
database enabled the identification of patients who underwent
an additional partial pancreatectomy during a gastrectomy.
Because multiple centers participated, we could evaluate the
outcomes of a reasonable large cohort of patients treated with
gastrectomy with partial pancreatectomy in the Netherlands in
the period 2011–2015.
One of the factors associated with improved survival was a
radical (pR0) resection. Previous studies also showed a de-
creased survival in patients in whom an R0 resection could







n % n % n %
55 9 16% 27 49% 19 35%
Indication pancreas resection
Tumor growth in pancreas 52 95% 9 100% 25 93% 18 95%
Intraoperative injury pancreas 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Lymph node dissection 3 5.5% 0 0.0% 2 7.4% 1 5.3%
Other 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Type of surgeon
Surgeon with expertise in pancreassurgerya 30 55% 7 78% 14 52% 9 47%
Surgeon with expertise in upper GI surgery 25 46% 2 22% 13 48% 10 53%
Change in surgical team
No 49 89% 8 89% 24 89% 17 90%
Yes, preoperative 2 3.6% 0 0.0% 1 3.7% 1 5.3%
Yes, intraoperative 4 7.3% 1 11% 2 7.4% 1 5.3%
Type of reconstruction
No 45 82% 3 33% 24 89% 18 95%
Pancreatico-jejunostomy, hepato-jejunostomy,
and gastro-jejunostomy
8 15% 6 67% 2 7.4% 0 0.0%
Other 2 3.6% 0 0.0% 1 3.7% 1 5.3%
Drain in pancreatic region (intraoperative)
Yes 16 29% 4 44% 5 19% 7 37%
No 39 71% 5 56% 22 82% 12 63%
Drain in pancreatic region (postoperative, percut.)
Yes 45 83% 7 78% 23 85% 15 83%
No 9 17% 2 22% 4 15% 3 17%
a In the last year
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not be achieved.13–16 In the present study, the percentage of
R0 resections was comparable between the group of patients
with partial pancreatectomy and without additional resections
(82% versus 85%, P = 0.82). In the current literature, the per-
centages R0 resections after multivisceral resections range
from 38 to 100%.17 Tran et al. reported an R0 resection
rate of 100% in 34 patients after additional partial
pancreatectomy.18
In this study, only 22% of patients with an additional partial
pancreatectomy had a cT4 tumor, and only 62% had a pT4
tumor at pathological examination. Ideally, a partial pancrea-
tectomy should only be performed in actual T4 tumors. In
other cohorts with multivisceral resections, low percentages
of pT4 tumors have been reported as well (14–80%).17 The
low percentage of patients with a cT4 tumor shows that there
is a discrepancy in the diagnostic assessment of tumor stage
with the intraoperative assessment. In order to distinguish a
cT3 tumor from a cT4 tumor in the preoperative phase,
endoscopic ultrasound (EUS), multidetector row computed
tomography (MDCT), and magnetic resonance imaging
(MRI) are preferred imaging methods.19 Also, when it is not
known whether there is ingrowth in the pancreas, it may be
recommended to perform an EUS, MDCT, or MRI. The re-
sults of the DUCA showed that in only 27% of patients EUS is
used for diagnostics. The use of MDCT and MRI were not
registered in the DUCA.
The low percentage of patients with a pT4 tumor shows
that there is a discrepancy in the intraoperative assessment of
tumor stage with the actual tumor stage as seen in pathological
examination. Intraoperative frozen section biopsy could be
used to assess the resection margin and to decide whether an
additonal pancreatectomy is needed. However, dissecting
through the tumor plane violates the principle of surgical on-
cology, i.e., en-bloc resection.
In the present study, patients treated with perioperative sys-
temic therapy had better survival. Selection bias might partly
Table 4 Short-term outcomes of patients with no additional resections versus patients with additional partial pancreatectomies
Gastrectomy alone Gastrectomy plus partial
pancreatectomy
P value
n = 1911 (97%) n = 55 (2.8%)
Mean Median [IQR] Mean Median [IQR]
Hospital stay (days) 14 9 [7–13] 23 14 [10–20] < 0.001
IC stay (days) 1.8 0 [0–1] 1.8 1[0–2] > 0.05
n % n % P value
Intraoperative complication 73 3.8% 1 1.8% 0.44
Postoperative complication 703 37% 33 60% < 0.001




In-hospital and 30-day mortality 101 5.3% 4 7.3% 0.52
Clavien–Dindo grade ≥ III complication 332 17% 21 38% < 0.001
Resection margins 0.82
R0 Microscopic radical 1617 85% 45 82%
R1 Microscopic irradical 202 11% 7 13%
R2 Loco regional residual tumor 25 1.3% 1 1.8%
Not applicable 21 1.1% 0 0.0%
Unknown 46 2.4% 2 3.6%
Multivariable analysis OR 95% CI P value
Association with Clavien–Dindo grade ≥ III complicationa < 0.001
No additional resection 1.00
Additional partial pancreatectomy 3.13 1.76–5.59
a Adjusted for age, sex, Charlson comorbidity score,11 ASA score, location tumor, type of resection (partial/total gastrectomy)
IC intensive care, R0 tumor-negative resection margins, R1 microscopically tumor-positive resection margins, R2 macroscopically tumor-positive
resection margins, IQR interquartile range, CI confidence interval, ASA American Society Anaesthesiologists
J Gastrointest Surg (2019) 23:2327–2337 2333
explain this difference. A recent study on the use of perioper-
ative therapy in Dutch patients showed that older patients and
patients with a higher ASA score had a lower probability for
initiation of perioperative therapy.20 In the present cohort, the
patients who were not treated with preoperative therapy might
have been frail patients who were unfit for undergoing preop-
erative therapy. These patients are probably more likely to die
which could have influenced the survival of this group.
Furthermore, exclusion for resection of patients that are pro-
gressive during perioperative therapy could have occurred.
These data are not available in our surgical database.
However, based on our results, it may be wise to take the
prognosis of patients without perioperative systemic therapy
into account. Patients who are not eligible for perioperative
systemic therapy may also not benefit from a partial pancrea-
tectomy during gastrectomy.
Since the MAGIC trial, perioperative chemotherapy for
gastric cancer gained importance.21 Since partial pancreatec-
tomies are associated with high complication rates, it is pos-
sible that patients who undergo a partial pancreatectomy can-
not be treated with adjuvant therapy. In the Dutch guideline,
perioperative chemotherapy is recommended for patients with
stage > 1 gastric cancer and are fit enough to undergo
chemotherapy.1 This study showed that 38% of patients in
the pancreatectomy group were not treated with neoadjuvant
therapy neither adjuvant therapy. A recent Dutch study
showed that patients with postoperative complications had a
threefold increased likelihood of not receiving adjuvant
therapy.22 It might thus be prudent to focus on a more intense
neoadjuvant systemic therapy to patients in whom a partial
pancreatectomy is considered. In the future, the results of the
CRITICS-II may help in choosing the best neoadjuvant ther-
apy. The CRITICS-II trial aims to optimize preoperative treat-
ment by comparing treatment regimens: (1) chemotherapy, (2)
chemotherapy followed by chemoradiotherapy, and (3)
chemoradiotherapy.23
The performance of additional partial pancreatectomy and
splenectomy in order to retrieve more lymph nodes abandoned
in the past because of its high postoperative morbidity.8, 9
The current study showed high postoperative morbidity in
gastrectomy patients with partial pancreatectomies.
Complications occurred in 60% of patients, and Clavien–
Dindo grade III and higher complications in 38% of patients.
Tran et al. reported also a significantly higher percentage of
Clavien-Dindo grade ≥ III complications for patients with gas-
tric cancer undergoing a gastrectomy with partial pancreatec-
tomy versus gastrectomy without multivisceral resection
(33% versus 17%).18,24 These results are comparable to pan-
creatic cancer patients: a recent study reported the postopera-
tive outcomes of partial pancreatectomies for pancreatic can-
cer in the Netherlands; they showed that 30% of patients had a
Clavien–Dindo grade III or higher complication.25
The survival rates in our study were comparable to those
reported in a recent study by Mita et al. evaluating additional
Table 5 Details of the partial pancreatectomies: treatment characteristics
Pancreatectomies
Total Pancreatoduodenectomy Distal pancreatectomy Minimal/wedge resection
n % n % n %
55 9 16% 27 49% 19 35%
Postoperative complications
No 22 40% 2 22% 10 37% 10 53%
Yes 33 60% 7 78% 17 63% 9 47%
POFPa
No POPF, no biochemical leakage 39 71% 6 67% 18 67% 15 79%
No POPF, but biochemical leakage 5 9.1% 1 11% 4 15% 0 0.0%
Yes, grade B 9 16% 2 22% 5 19% 2 11%
Yes, grade C 2 3.6% 0 0.0% 0 0.0% 2 11%
Clavien-Dindo grade ≥ III complication
No 34 62% 3 33% 19 70% 12 63%
Yes 21 38% 6 67% 8 30% 7 37%
30-day/in-hospital mortality
No 51 93% 8 89% 26 96% 17 90%
Yes 4 7.3% 1 11% 1 3.7% 2 11%
aAccording to the definition of Bassi&ISGPS, Surgery 2016
POPF postoperative pancreatic fistula
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partial pancreatectomies for gastric cancer. They reported a 1-
year survival rate of 62% and a 3-year survival rate of 35%
(versus respectively 56% and 31% in the present cohort).26
Likewise, the 3-year survival rates of patients with pT4 gastric
cancer who underwent multivisceral resections are compara-
ble with the outcomes in our cohort.27 Compared to the 2-year
survival rate of all potentially curative gastric cancer patients
in the Netherlands, the survival of this cohort is poor.28 Van
Putten et al. reported national 2-year survival rates varying
between 38 and 50%, depending on the variation in surgical
treatment probability between hospitals.
A limitation of this study was that a pancreatectomy for
gastric cancer was not common and not all hospitals in the
Netherlands participated in the data collection for patients
with partial pancreatectomy. All hospitals have been
contacted to participate. The hospitals that did not partici-
pate indicated that the reason was of a logistical nature (no
time). A second limitation was that survival information
was not available for the patients with gastrectomy only.
Another limitation was that it was not possible to deter-
mine the independent influence of individual parameters
on survival because the number of patients undergoing
partial pancreatectomy was relatively limited. Because of
this limited number of patients, no conclusions could be
drawn regarding the different types of pancreatectomies.
In conclusion, the present study showed that a gastrectomy
in combination with a partial pancreatectomy might be con-
sidered as a valid curative treatment option for gastric cancer.
The reported morbidity and mortality after partial pancreatec-
tomy for gastric cancer are at least comparable to rates after
partial pancreatectomy for pancreatic cancer. Therefore, de-
spite the high morbidity, it may be worthwhile to perform a
partial pancreatectomy in patients with gastric cancer when
the tumor is directly invading into the pancreas. It should
probably be reserved for patients with a T4 tumor in whom
an R0 resection is feasible. Preoperative and intraoperative
selection of patients for additional partial pancreatectomy
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Fig. 2 Survival of patients with partial pancreatectomy
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